Summary:
Symbiotec Pharmalab's ₹1,757 crore IPO was subscribed 0.80x on Day 1, with employees leading at 1.52x and NIIs at 1.04x. Retail participation stood at 0.94x, while QIB demand remained subdued at 0.35x. Investors will watch institutional participation closely as bidding continues until August 27.
Symbiotec Pharmalab, the Indore-based pharmaceutical and biotechnology company, opened its ₹1,757 crore mainboard IPO for subscription on August 24, 2026. The issue got off to a subdued start, subscribed 0.80 times overall by the end of Day 1.
IPO Details
| Detail | Information |
| Issue Size | ₹1,757 crore (fresh issue ₹150 crore + OFS ₹1,607 crore) |
| Price Band | ₹938–₹988 per share |
| Lot Size | 15 shares |
| Minimum Investment (Retail) | ₹14,820 |
| Face Value | ₹2 per share |
| IPO Open Date | August 24, 2026 |
| IPO Close Date | August 27, 2026 |
| Registrar | MUFG Intime India Pvt Ltd |
| Book-Running Lead Managers | JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, Nomura Financial Advisory |
Category-wise Breakdown on Day 1
| Category | Shares Offered/Reserved | Shares Bid For | Subscription (x) |
| Qualified Institutional Buyers (QIBs) | 37,39,872 | 13,26,390 | 0.35 |
| Non Institutional Investors | 28,04,904 | 29,05,065 | 1.04 |
| — NII (bids above ₹10 lakh) | 18,69,936 | 14,46,150 | 0.77 |
| — NII (bids ₹2–10 lakh) | 9,34,968 | 14,58,915 | 1.56 |
| Retail Individual Investors (RIIs) | 65,44,776 | 61,82,405 | 0.94 |
| Employees | 35,377 | 53,850 | 1.52 |
| Total | 1,31,24,929 | 1,04,47,710 | 0.80 |
Data as of 24-Aug-2026, 4:48 PM IST, sourced from NSE Consolidated Bid Details (nseindia.com).
Symbiotec Pharmalab IPO - Day 1 Subscription Status
As of the update on August 24, 2026, the issue received bids for 1,04,47,710 shares against 1,31,24,929 shares on offer, taking overall subscription to 0.80 times. Employees led the modest demand at 1.52 times, followed by Non-Institutional Investors at 1.04 times and Retail Individual Investors at 0.94 times, while Qualified Institutional Buyers stayed muted at 0.35 times.
What Day 1 Numbers Indicate
Subscription staying below the 1x mark across most categories on Day 1 is not unusual for large, high-priced mainboard issues, where investors often wait to gauge broader sentiment before committing capital. The relatively even response across NII and retail categories, both hovering close to full subscription, suggests steady rather than aggressive early interest. Within the NII category, the ₹2–10 lakh bracket (1.56x) outpaced the above-₹10-lakh bracket (0.77x), pointing to smaller HNIs moving somewhat ahead of larger applicants. With QIB bidding still muted at 0.35 times, institutional demand — which typically surges on the final day of mainboard issues — will be the key factor determining the issue's overall subscription level by close on August 27.
Symbiotec Pharmalab IPO - Timetable
| Event | Date |
| Anchor Bid Date | August 21, 2026 |
| IPO Open Date | August 24, 2026 |
| IPO Close Date | August 27, 2026 |
| Allotment Finalisation | August 28, 2026 |
| Refund/Demat Credit | August 31, 2026 |
| Listing Date | September 1, 2026 |
| Listing Exchanges | BSE, NSE |
Should You Apply for Symbiotec Pharmalab IPO?
Incorporated in 2002 and headquartered in Indore, Symbiotec Pharmalab is a research and development-driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology, and complex injectables. The company's business spans corticosteroid and steroidal-hormone active pharmaceutical ingredients, along with nutritional ingredients and specialty products, serving both domestic and international regulated and emerging markets. Revenue grew 15% year-on-year to ₹872.26 crore in FY26, with profit after tax rising 14% to ₹109.90 crore.
Investors considering the issue should weigh the company's specialised API capabilities, steady revenue and profit growth, and exposure to regulated international markets against risks typical of the pharmaceutical API business, such as regulatory compliance requirements across geographies and pricing pressure in commoditised segments. As with any IPO, the decision should be based on individual risk appetite, investment horizon, and a review of the RHP rather than subscription numbers alone.
How to Apply for Symbiotec Pharmalab IPO
Investors can apply for the Symbiotec Pharmalab IPO through ASBA via their bank's net banking portal, via UPI-based ASBA through their stock broker's trading app, or offline by submitting a physical ASBA form through their broker. The minimum lot size is 15 shares, requiring a minimum investment of approximately ₹14,820 at the upper price band.
How to Check Symbiotec Pharmalab IPO Subscription Status
How to check Symbiotec Pharmalab IPO Subscription Status on NSE website
- Visit the NSE IPO issue information page (nseindia.com).
- Search for "Symbiotec Pharmalab" or enter the symbol SYMBIOTEC.
- Select "Consolidated Bid Details" from the dropdown to view category-wise subscription data.
- The page refreshes periodically to show live bidding figures during market hours.
How to check Symbiotec Pharmalab IPO Subscription Status on BSE website
- Visit the BSE IPO page (bseindia.com).
- Navigate to the "Active IPO" or "IPO Bidding" section.
- Select "Symbiotec Pharmalab Limited" from the list of active issues.
- View category-wise and overall subscription figures, updated through the bidding window.
How to check Symbiotec Pharmalab IPO Subscription Status on Ventura?
Ventura clients can track real-time subscription status for the Symbiotec Pharmalab IPO directly within the IPO section of the Ventura app or web platform, alongside category-wise bid data and allotment updates — without needing to switch between exchange websites.
Conclusion
Symbiotec Pharmalab's IPO opened on a quiet note, with Day 1 subscription at 0.80 times overall, as investors held back across most categories. With three more days of bidding ahead until the issue closes on August 27, subscription numbers will need to build meaningfully — particularly from institutional investors, whose demand typically surges in the final session of mainboard issues.
